Clinical Trial: Fuzheng Huayu Tablets plus Anti-HBV Therapy for Liver Fibrosis or Early Cirrhosis in Patients with Chronic Hepatitis B and Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (China)

China, Sept. 3 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Fuzheng Huayu Tablets plus Anti-HBV Therapy for Liver Fibrosis or Early Cirrhosis in Patients with Chronic Hepatitis B and Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Trial'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131412

Registration Time: 2026/09/02

Type: Interventional study

Primary Sponsor: The Third Affiliated Hospital Sun Yat-sen University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=302332

Published by HT Digital Content Services with permission from Health Daily Digest....